\-\ Texto\\:\\ \ \(0\)\
\-\ negative\\ ppd\ \(1\)\
\-\ increased\\ vascularity\\ on\\ cxr\ \(0\)\
\-\ chemotherapy\\ trial\ \(3\)\
\-\ admission\\ for\\ complications\ \(1\)\
\-\ rul\\ peribronchial\\ cuffing\\ with\\ rt\\ hilar\\ soft\\ tissue\\ mass\\.\\ multiple\\ tiny\\ nodules\\ distal\\ to\\ pulmonary\\ mass\\ and\\ cuffing\\.\ \(0\)\
\-\ lymphangitic\\ carcinomatosis\\ secondary\\ to\\ non\\-small\\ cell\\ lung\\ ca\ \(0\)\
\-\ tb\ \(176\)\
\-\ invasive\\ fungal\\ infection\ \(0\)\
\-\ sarcoid\ \(163\)\
\-\ lymphoma\ \(373\)\
\-\ 4\\ week\\ hx\\ increasing\\ hemoptysis\\ with\\ significant\\ smoking\\ hx\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cuffing\\:\\ 0\\.24948432897358006\ \(0\)\
\-\ hx\\:\\ 0\\.15668707204799726\ \(0\)\
\-\ peribronchial\\:\\ 0\\.11723355137367587\ \(0\)\
\-\ rul\\:\\ 0\\.11190610558753178\ \(0\)\
\-\ non\\-small\\:\\ 0\\.10777381760023161\ \(0\)\
\-\ lymphangitic\\:\\ 0\\.10518563348217312\ \(0\)\
\-\ ppd\\:\\ 0\\.10291522011009288\ \(0\)\
\-\ rt\\:\\ 0\\.10291522011009288\ \(0\)\
\-\ trial\\:\\ 0\\.09965798554595096\ \(0\)\
\-\ tiny\\:\\ 0\\.09907004668827354\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.09688887936130348\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.09117959492325688\ \(0\)\
\-\ vascularity\\:\\ 0\\.08742914558785922\ \(0\)\
\-\ sarcoid\\:\\ 0\\.08119817824302192\ \(0\)\
\-\ smoking\\:\\ 0\\.07992053247474505\ \(0\)\
\-\ hilar\\:\\ 0\\.07951351568365662\ \(0\)\
\-\ invasive\\:\\ 0\\.07951351568365662\ \(0\)\
\-\ fungal\\:\\ 0\\.07671647387971466\ \(0\)\
\-\ tb\\:\\ 0\\.07620440848470521\ \(0\)\
\-\ ca\\:\\ 0\\.07368956512990778\ \(0\)\
\-\ admission\\:\\ 0\\.06973448919846224\ \(0\)\
\-\ cxr\\:\\ 0\\.06677837539120514\ \(0\)\
\-\ nodules\\:\\ 0\\.06560220121116206\ \(0\)\
\-\ increasing\\:\\ 0\\.06485763786897612\ \(0\)\
\-\ complications\\:\\ 0\\.0627069036113344\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.05672121824334935\ \(0\)\
\-\ week\\:\\ 0\\.053741026265337555\ \(0\)\
\-\ negative\\:\\ 0\\.04726148446990508\ \(0\)\
\-\ pulmonary\\:\\ 0\\.046232413152223394\ \(0\)\
\-\ infection\\:\\ 0\\.0460003069272742\ \(0\)\
\-\ lung\\:\\ 0\\.04583628000442122\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04522590063684233\ \(0\)\
\-\ secondary\\:\\ 0\\.044241295676089025\ \(0\)\
\-\ 4\\:\\ 0\\.04409207231813046\ \(0\)\
\-\ mass\\:\\ 0\\.04401707433139128\ \(0\)\
\-\ distal\\:\\ 0\\.04302367757307457\ \(0\)\
\-\ cell\\:\\ 0\\.04274519836262011\ \(0\)\
\-\ significant\\:\\ 0\\.042552725019522654\ \(0\)\
\-\ increased\\:\\ 0\\.038712681144438064\ \(0\)\
\-\ soft\\:\\ 0\\.03853568081469537\ \(0\)\
\-\ tissue\\:\\ 0\\.03750779978615914\ \(0\)\
\-\ multiple\\:\\ 0\\.03332974080517164\ \(0\)\
\-\ to\\:\\ 0\\.01581733734974023\ \(0\)\
\-\ for\\:\\ 0\\.013502002752642872\ \(0\)\
\-\ on\\:\\ 0\\.013405389117878298\ \(0\)\
\-\ with\\:\\ 0\\.004333488003329249\ \(0\)\
\-\ and\\:\\ 0\\.0033335001061521935\ \(0\)\
\-\ \\.\\:\\ 0\\.0013147976332350472\ \(0\)\
